MIRMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Mirum Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$82.24+2.10 (+2.62%)
Close on Oct 19, 2026
- Market cap
- $5.21B
- P/E (TTM)
- –
- Dividend yield
- –
Mirum Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Mirum Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $5.34B | $166.30M |
| Enterprise Value | $4.90B | $88.19M |
| PS Ratio | 8.64 | 3.65 |
Enterprise value
| Measure | Mirum Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | 7.93 | 2.51 |
Income (trailing twelve months)
| Measure | Mirum Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $618.07M | $58.34M |
| Operating Income | -$833.97M | -$21.40M |
| Pretax Income | -$857.54M | -$14.34M |
| Net Income | -$860.21M | -$22.46M |
| EBITDA | -$808.02M | -$16.91M |
| EPS (Diluted) | -$14.55 | -$0.83 |
Margins
| Measure | Mirum Pharmaceuticals | Industry median |
|---|---|---|
| Operating Margin | -134.9% | -44.0% |
| Pretax Margin | -138.7% | -13.3% |
| Profit Margin | -139.2% | -40.2% |
| EBITDA Margin | -130.7% | -30.2% |
| FCF Margin | -37.0% | -9.27% |
Returns
| Measure | Mirum Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | -703.0% | -53.2% |
| Return on Assets (ROA) | -97.2% | -40.9% |
| Return on Capital Employed (ROCE) | -101.4% | -38.1% |
Growth
| Measure | Mirum Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 44.0% | 5.96% |
| FCF Growth (YoY) | -2751.5% | 2.34% |
| Revenue Growth (3Y CAGR) | 89.1% | 2.25% |
Balance sheet
| Measure | Mirum Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $438.29M | $61.43M |
| Net Cash (Debt) | $438.29M | $15.35M |
| Net Cash Per Share | $6.75 | $0.66 |
| Equity (Book Value) | -$10.42M | $49.09M |
| Book Value Per Share | -$0.16 | $1.37 |
| Tangible Book Value | -$257.81M | $23.52M |
| Working Capital | $413.52M | $76.81M |
Financial position
| Measure | Mirum Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 2.86 | 3.34 |
| Quick Ratio | 2.62 | 2.44 |
| Interest Coverage | -62.06 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Mirum Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$227.27M | -$12.35M |
| Capital Expenditures | -$1.47M | -$1.08M |
| Free Cash Flow | -$228.74M | -$20.22M |
| FCF Per Share | -$3.52 | -$0.42 |
Efficiency
| Measure | Mirum Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.70 | 0.39 |
| Revenue Per Employee | $1.66M | $404.87K |
| Profits Per Employee | -$2.31M | -$703.34K |
| Employee Count | 372 | 74 |
Dividends and yields
| Measure | Mirum Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -16.1% | -23.3% |
| FCF Yield | -4.28% | -8.72% |
Shares
| Measure | Mirum Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 64,932,200 | 58,127,000 |
| Shares Change (YoY) | 18.6% | 10.9% |
| Shares Change (QoQ) | 6.28% | 0.54% |
| Float | 58,984,300 | 49,136,700 |
| Shares Held by Insiders | 9.16% | 11.6% |
| Shares Held by Institutions | 110.0% | 59.4% |
Taxes
| Measure | Mirum Pharmaceuticals | Industry median |
|---|---|---|
| Income Tax | $2.67M | $79.87K |
Scores
| Measure | Mirum Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | -0.57 | -0.22 |
| Piotroski F-Score | 5 | 4 |
Calculated by StockData from Mirum Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.